Launching the Clostridioides difficile collection

References

1. Smits WK, Lyras D, Lacy DB, Wilcox MH, Kuijper EJ. Clostridium difficile infection. Nat Rev Dis Primers 2016; 2:16020 [View Article] [PubMed]
   [Google Scholar]
2. Di Bella S, Sanson G, Monticelli J, Zerbato V, Principe L et al. Clostridioides difficile infection: history, epidemiology, risk factors, prevention, clinical manifestations, treatment, and future options. Clin Microbiol Rev 2024; 37:e00135–23 [View Article] [PubMed]
   [Google Scholar]
3. Wingen-Heimann SM, Davies K, Viprey VF, Davis G, Wilcox MH et al. Clostridioides difficile infection (CDI): A pan-European multi-center cost and resource utilization study, results from the Combatting Bacterial Resistance in Europe CDI (COMBACTE-CDI). Clin Microbiol Infect 2023; 29:651 [View Article] [PubMed]
   [Google Scholar]
4. Viprey VF, Davis GL, Benson AD, Ewin D, Spittal W et al. A point-prevalence study on community and inpatient Clostridioides difficile infections (CDI): results from Combatting Bacterial Resistance in Europe CDI (COMBACTE-CDI), July to November 2018. Euro Surveill 2022; 27:2100704 [View Article] [PubMed]
   [Google Scholar]
5. Boekhoud IM, Hornung BVH, Sevilla E, Harmanus C, Bos-Sanders IMJG et al. Plasmid-mediated metronidazole resistance in Clostridioides difficile. Nat Commun 2020; 11:598 [View Article] [PubMed]
   [Google Scholar]
6. Olaitan AO, Dureja C, Youngblom MA, Topf MA, Shen W-J et al. Decoding a cryptic mechanism of metronidazole resistance among globally disseminated fluoroquinolone-resistant Clostridioides difficile. Nat Commun 2023; 14:4130 [View Article] [PubMed]
   [Google Scholar]
7. Marchandin H, Anjou C, Poulen G, Freeman J, Wilcox M et al. In vivo emergence of a still uncommon resistance to fidaxomicin in the urgent antimicrobial resistance threat Clostridioides difficile. J Antimicrob Chemother 2023; 78:1992–1999 [View Article] [PubMed]
   [Google Scholar]
8. Darkoh C, Keita K, Odo C, Oyaro M, Brown EL et al. Emergence of clinical Clostridioides difficile isolates with decreased susceptibility to vancomycin. Clin Infect Dis 2022; 74:120–126 [View Article] [PubMed]
   [Google Scholar]
9. Lim SC, Knight DR, Riley TV. Clostridium difficile and one health. Clin Microbiol Infect 2020; 26:857–863 [View Article] [PubMed]
   [Google Scholar]
10. Puleston R, Roulston K, Morgan K, Hopkins S, Wilcox MH et al. Emergence of new concerning ribotype of Clostridioides difficile (955), O0430, ESCMID Global Congress, April 27-30. Barcelona, Spain: 2024 [PubMed]